Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Single-arm, Open-label Study to Evaluate the Safety and Efficacy of MGTA-456 in Patients With Inherited Metabolic Disorders (IMD) Undergoing Hematopoietic Stem Cell Transplantation (HSCT)

Trial Profile

A Phase 2, Single-arm, Open-label Study to Evaluate the Safety and Efficacy of MGTA-456 in Patients With Inherited Metabolic Disorders (IMD) Undergoing Hematopoietic Stem Cell Transplantation (HSCT)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Dec 2018

At a glance

  • Drugs Spanlecortemlocel (Primary) ; Antithymocyte globulin; Busulfan; Cyclophosphamide; Fludarabine; Methylprednisolone
  • Indications Transplant rejection
  • Focus Therapeutic Use
  • Sponsors Magenta Therapeutics
  • Most Recent Events

    • 04 Dec 2018 Results of preliminary analysis Demonstrating Engraftment with Minimal Neutropenia with Mgta-456, a CD34+ Expanded Cord Blood (CB) Product Blood product, presented at the 60th Annual Meeting and Exposition of the American Society of Hematology.
    • 05 Apr 2018 According to Magenta Therapeutics media release, first patient have been Transplanted with MGTA-456 .
    • 25 Jan 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top